Skip to main
PRQR
PRQR logo

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics (PRQR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProQR Therapeutics NV is positioned for potential stock price appreciation due to the prospects of successfully advancing its pipeline products and achieving proof of concept data in human trials. The company’s promising Axiomer RNA base-editing platform is anticipated to provide clinical data that could significantly enhance its valuation. Additionally, with a robust cash position that supports operations into mid-2027, ProQR is strategically equipped to navigate its clinical development timeline.

Bears say

ProQR Therapeutics NV reported a net loss of €12.2 million for the quarter, a substantial increase compared to the €2.7 million loss in the same period in 2024, reflecting escalating financial challenges. The company's reliance on the outcomes of future Phase Ib/II/III studies presents significant uncertainty, as negative results could severely impact investor confidence and stock performance. Additionally, advancements in treatment methods for the diseases ProQR targets could potentially render the company's RNA-based therapies obsolete, further jeopardizing its market position and long-term viability.

ProQR Therapeutics (PRQR) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProQR Therapeutics (PRQR) Forecast

Analysts have given ProQR Therapeutics (PRQR) a Buy based on their latest research and market trends.

According to 7 analysts, ProQR Therapeutics (PRQR) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProQR Therapeutics (PRQR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.